Access cutting-edge solid tumors treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access solid tumors specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors treatment provided free
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Sponsor: Children's Oncology Group
Check if you qualify for this solid tumors clinical trial in Palo Alto, CA
If you're searching for solid tumors treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.